Results 31 to 40 of about 306,339 (298)

mTORC1-driven accumulation of the oncometabolite fumarate as a potential critical step in renal cancer progression

Molecular & Cellular Oncology, 2019
Modeling renal cancer in the mouse has been challenging. We recently showed that upregulation of mechanistic target of rapamycin complex 1 (mTORC1) in a restricted segment of the renal tubule leads to downregulation of the tricarboxylic acid (TCA) cycle ...
Luca Drusian, Alessandra Boletta
doaj   +1 more source

Molecular mechanisms of pain regulation in patients with osteoarthritis

Научно-практическая ревматология, 2016
Objective: to study the mechanisms determining the level of pain on the basis of an analysis of the expression profiles of the genes involved in joint destruction, inflammation, and metabolic regulation in the blood of patients with osteoarthritis (OA ...
E. V. Chetina, G. A. Markova, E. A. Taskina, E. P. Sharapova, N. G. Kashevarova, L. I. Alekseeva, V. V. Kolomatsky, M. A. Makarov, A. L. Logunov, S. A. Makarov, A. N. Kuzin   +10 more
doaj   +1 more source

Phosphatidic acid: a lipid regulator of the Hippo pathway

Molecular & Cellular Oncology, 2019
The Hippo pathway, a signaling pathway highly conserved across species, plays a crucial role in organ size control and cancer suppression. Our recent study shows that phosphatidic acid can regulate the Hippo pathway through a physical lipid-protein ...
Han Han, Rebecca Vargas, Gayoung Seo, Wenqi Wang   +3 more
doaj   +1 more source

Deconvoluting mTOR biology [PDF]

Cell Cycle, 2012
In metazoans, TOR is an essential protein that functions as a master regulator of cellular growth and proliferation. Over the past decade, there has been an explosion of information about this critical master kinase, ranging from the composition of the TOR protein complex to its ability to act as an integrator of numerous extracellular signals ...
Weber, Jason D, Gutmann, David H
openaire   +3 more sources

mTOR signaling at a glance [PDF]

Journal of Cell Science, 2009
The mammalian target of rapamycin (mTOR) signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival.
Mathieu, Laplante, David M, Sabatini
openaire   +2 more sources

Oxydative stress in type 2 diabetic patients: involvement of HIF-1 alpha AND mTOR genes expression [PDF]

The Ukrainian Biochemical Journal, 2023
Biochemical and genetic mechanisms of oxidative stress (OS) developing in the blood of patients with type 2 Diabetes mellitus (T2DM) were studied. Twenty patients with T2DM and 10 healthy persons participated in this study.
Y. A. Saenko, O. O. Gonchar, I. M. Mankovska, T. I. Drevytska, L. V. Bratus, B. M. Mankovsky   +5 more
doaj   +1 more source

mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors [PDF]

Endocrine-Related Cancer, 2016
Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This study was aimed to identify the possible predictive markers of response to Everolimus in P-NET. We found that Everolimus reduced the cell viability and induced
FALLETTA, Simona, Partelli, Stefano, Rubini, Corrado, Nann, Dominik, Doria, Andrea, Marinoni, Ilaria, Polenta, Vanessa, DI PASQUALE, Carmelina, DEGLI UBERTI, Ettore, Perren, Aurel, Falconi, Massimo, ZATELLI, Maria Chiara   +11 more
openaire   +3 more sources

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor [PDF]

Nature, 2016
Precision medicines exert selective pressure on tumour cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next-generation therapies to treat the evolving cancer. The PIK3CA-AKT-mTOR pathway is one of the most commonly activated pathways in human cancers, which has led to the development of small ...
Rodrik-Outmezguine, Vanessa S., Okaniwa, Masanori, Yao, Zhan, Novotny, Chris J., McWhirter, Claire, Banaji, Arpitha, Won, Helen, Wong, Wai, Berger, Mike, de Stanchina, Elisa, Barratt, Derek G., Cosulich, Sabina, Klinowska, Teresa, Rosen, Neal, Shokat, Kevan M.   +14 more
openaire   +2 more sources

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

Updates of mTOR Inhibitors [PDF]

Anti-Cancer Agents in Medicinal Chemistry, 2010
Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism and angiogenesis. mTOR signaling is often dysregulated in various human diseases and thus attracts great interest in developing drugs that target mTOR.
Hongyu, Zhou, Yan, Luo, Shile, Huang
openaire   +2 more sources